Home Newsfeeds Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target

Jefferies Downgrades Vertex Pharmaceuticals to Hold, Announces $340 Price Target

Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.

byBenzinga Newsdesk

December 19, 2022

1 minute read

Jefferies analyst Michael Yee downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and announces $340 price target.

U.S. Bancorp Exceeds Expectations with 29% Jump In Adjusted Net Interest Income, Well-Positioned For Revenue Growth Strategies

By Anusuya Lahiri

July 19, 8:30 AM

U.S. Bancorp (NYSE: USB) clocked a second-quarter total adjusted net revenue growth of 19.7% year-over-year to $7.197 billion. Net interest income plus Noninterest income totaled $7.141 billion.

USB

Delete WhatsApp, Telegram Founder Warns: What The Bezos Incident Shows Us About Meta’s App

By Ananya Gairola

December 24, 11:19 PM

WhatsApp "has now been a surveillance tool for 13 years," according to Telegram founder Pavel Durov, who says he deleted the Meta Platforms Inc. (NASDAQ: META) app from his devices "years ago."

AAPL

$1000 Invested In Shopify 5 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 15, 2:29 PM

Shopify (NYSE:SHOP) has outperformed the market over the past 5 years by 21.23% on an annualized basis producing an average annual return of 33.26%. Currently, Shopify has a market capitalization of $50.37 billion.

SHOP